tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Miyauchi T et al. Effect of donor-specific splenocytes via portal vein and FK506 in rat small bowel transplantation. 1998 Transplantation pmid:9448139
O'Grady J C(2) monitoring: out of the blocks but with some way to go! 2004 Transplantation pmid:15201659
Koprak S et al. Depletion of the mature CD4+8- thymocyte subset by FK506 analogs correlates with their immunosuppressive and calcineurin inhibitory activities. 1996 Transplantation pmid:8623162
Tsuchiya N et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. 2004 Transplantation pmid:15502717
Josephson MA et al. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. 2004 Transplantation pmid:15502727
Yamagami S et al. Mechanism of concordant corneal xenograft rejection in mice: synergistic effects of anti-leukocyte function-associated antigen-1 monoclonal antibody and FK506. 1997 Transplantation pmid:9233699
Johnson MC et al. QT prolongation and Torsades de Pointes after administration of FK506. 1992 Transplantation pmid:1373538
van Hooff JP et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. 2003 Transplantation pmid:12829890
Stegall MD et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. 1997 Transplantation pmid:9422416
Donnadieu B et al. Central retinal vein occlusion-associated tacrolimus after liver transplantation. 2014 Transplantation pmid:25955343
Kasahara M et al. Living-related liver transplantation for type II citrullinemia using a graft from heterozygote donor. 2001 Transplantation pmid:11211185
Ovuworie CA et al. Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. 2001 Transplantation pmid:11685108
Al-Uzri A et al. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). 2001 Transplantation pmid:11579294
Mourad G et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. 2001 Transplantation pmid:11579299
Vacher-Coponat H et al. Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine. 2006 Transplantation pmid:16926601
Ciancio G et al. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. 2011 Transplantation pmid:22027927
Mor E et al. Late-onset acute rejection in orthotopic liver transplantation--associated risk factors and outcome. 1992 Transplantation pmid:1279849
Shapiro R et al. Posttransplant diabetes in pediatric recipients on tacrolimus. 1999 Transplantation pmid:10096540
Prud'homme GJ et al. GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone. 2013 Transplantation pmid:23851932
Nashan B et al. Clinical validation studies of Neoral C(2) monitoring: a review. 2002 Transplantation pmid:12023607
Andoh TF et al. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. 1994 Transplantation pmid:7509514
Bäckman L et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. 1994 Transplantation pmid:7509516
Tanaka M et al. Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. 1996 Transplantation pmid:8830837
Ekberg H et al. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. 2009 Transplantation pmid:19424036
Mestres J et al. Late subcapsular lymphocele in a kidney graft. 2012 Transplantation pmid:22487814
Jain A et al. Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. 2001 Transplantation pmid:11374410
Cherikh WS et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. 2003 Transplantation pmid:14627905
Ochiai T et al. Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. 1989 Transplantation pmid:2474208
Sommerer C et al. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. 2010 Transplantation pmid:20463649
Becker T et al. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. 2008 Transplantation pmid:19104406
Froud T et al. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. 2008 Transplantation pmid:19104407
Muraki T et al. Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. 1995 Transplantation pmid:7544038
Yamani MH et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. 2000 Transplantation pmid:10868634
Verleden GM et al. Successful conversion from cyclosporine to tacrolimus for gastric motor dysfunction in a lung transplant recipient. 2002 Transplantation pmid:12131703
Johnson C et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. 2000 Transplantation pmid:10755536
Ekser B et al. Hepatic function after genetically engineered pig liver transplantation in baboons. 2010 Transplantation pmid:20606605
Alloway R et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. 2007 Transplantation pmid:17589351
Jain AB et al. Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. 1995 Transplantation pmid:7545836
Vincenti F et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8669100
Uchikoshi F et al. Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. 1996 Transplantation pmid:8669109
Dieterle CD et al. Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. 2004 Transplantation pmid:15239622
Meiser BM and Reichart B New trends in clinical immunosuppression. 1994 Transplant. Proc. pmid:7527954
Nakajima K et al. Effects of triple therapy of cyclosporine, FK 506, and RS-61443 on allogeneic small bowel transplantation in dogs. 1993 Transplant. Proc. pmid:7679821
Ohtsuka S et al. Hamster-to-rat xenotransplantation of whole pancreas by FK 506 combined with splenectomy. 1994 Transplant. Proc. pmid:7513473
Risaliti A et al. Cardiovascular and metabolic complications after liver transplantation: Neoral- versus tacrolimus-based immunosuppression. 2001 Nov-Dec Transplant. Proc. pmid:11750569
Goto T et al. FK 506: historical perspectives. 1991 Transplant. Proc. pmid:1721254
Ciancio G et al. Current advantage of FK 506 in cadaveric kidney transplantation. 1996 Transplant. Proc. pmid:8623207
Vanrenterghem Y et al. Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. 1998 Transplant. Proc. pmid:9636523
Tanabe K et al. Japanese single-center experience of kidney transplantation under tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11119897
Bruce DS et al. Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9532150
Gutiérrez Sánchez MJ et al. Optimization of immunosuppression by switching from azathioprine to enteric-coated mycophenolate sodium in stable kidney transplant patients. 2009 Jul-Aug Transplant. Proc. pmid:19715907
Rafecas A et al. Immunosuppression with calcineurin inhibitors and polyclonal antibodies in liver transplantation. 2002 Transplant. Proc. pmid:11959209
Müller MK et al. Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. 1991 Transplant. Proc. pmid:1721286
Mueller AR et al. Does initial graft function influence the outcome after liver transplantation? 1998 Transplant. Proc. pmid:9636594
Oishi M et al. A case of hyperkalemic distal renal tubular acidosis secondary to tacrolimus in living donor liver transplantation. 2000 Transplant. Proc. pmid:11120143
Soriano S et al. Single-center experience with initial intravenous dosing of tacrolimus after kidney transplantation. 1999 Transplant. Proc. pmid:10576045
Serrano M et al. Clinical value of a single determination of intracellular ATP levels in stimulated CD4+ T lymphocytes in pediatric patients with stable liver transplantation. 2012 Transplant. Proc. pmid:23146475
Takeuchi H et al. Lymphocyte sensitivity to cyclosporine and tacrolimus in chronic renal failure patients and clinical significance in renal transplantation. 1998 Transplant. Proc. pmid:9474950
Liu M et al. C4d-positive acute humoral renal allograft rejection: rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil. 2004 Transplant. Proc. pmid:15518760
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Hayashi S et al. Synergistic effect of donor pretreatment using FK 506 in hamster-to-rat cardiac xenotransplantation. 1994 Transplant. Proc. pmid:7518126
Woodle ES et al. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection. 1993 Transplant. Proc. pmid:7682358
Senninger N et al. Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506. 1995 Transplant. Proc. pmid:7533364
Yagihashi A et al. The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721318
Malireddy SR et al. Altered first-pass effects in a liver transplant recipient explained intraindividual variation in calcineurin inhibitor concentrations: a case report. 2008 Transplant. Proc. pmid:18589198
Braun F et al. Therapeutic drug monitoring of tacrolimus early after liver transplantation. 2002 Transplant. Proc. pmid:12176473
Tashiro H et al. Monitoring for engraftment of rat orthotopic liver transplantation by semiquantitative PCR. 1995 Transplant. Proc. pmid:7533421
Schorlemmer HU et al. Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. 1998 Transplant. Proc. pmid:9865312
Felser I et al. Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721350
Chiereghin A et al. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients. 2010 Jan-Feb Transplant. Proc. pmid:20172283
Nanni G et al. Lack of correlation between serum levels of mycophenolate mofetil and kidney transplant outcome in tacrolimus-based immunosupression. 2002 Transplant. Proc. pmid:12270323
Chmiel B et al. Rheological properties of red blood cells in kidney transplant recipients: the role of lipid profile and type of immunosuppresion. 2005 Transplant. Proc. pmid:15919493
Walgenbach KJ et al. Increased presence of mast cells and interleukin-4 during chronic rejection of rat intestinal allografts. 1996 Transplant. Proc. pmid:8907896
Miyagi M et al. Comparison of the therapeutic effects between CsA and FK506 on chronic renal allograft injury and TGF-beta expression. 2002 Transplant. Proc. pmid:12176497
Zmonarski SC et al. Lowering of Messenger Ribonucleic Acid Toll-Like Receptors 2-4,9 in Peripheral Blood Mononuclear Cells in Kidney Allograft Recipients, Relationships With Immunosuppressive Treatment, and Delayed Graft Function Occurrence. 2016 Transplant. Proc. pmid:27496439
Endoh M et al. Nonmuscle myosin heavy chain and metalloproteinase-2 expression in concordant pulmonary xenografts. 2000 Transplant. Proc. pmid:10936397
Citterio F et al. Steroid withdrawal from tacrolimus-based therapy in renal transplant patients. 2002 Transplant. Proc. pmid:12176545
Han DJ et al. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen. 2012 Transplant. Proc. pmid:22310592
Chang HR et al. Lack of hepatotoxicity upon sirolimus addition to a calcineurin inhibitor-based regimen in hepatitis virus-positive renal transplant recipients. 2007 Transplant. Proc. pmid:17580178
Jiang H et al. IL-10: a tacrolimus-specific cytotoxic mediator in ongoing allograft rejection. 2001 Feb-Mar Transplant. Proc. pmid:11266931
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation in rats. 1991 Transplant. Proc. pmid:1721413
Tanabe K et al. Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression. 1996 Transplant. Proc. pmid:8658670
Cirocco RE et al. Kidney recipient CMV incidence in the gancyclovir era: monitoring viral DNA by a CMV-PCR assay. 1999 Feb-Mar Transplant. Proc. pmid:10083604
Nakao A et al. Cytokine mRNA expression on rat small bowel allograft treated with tacrolimus and simultaneous bone marrow transplantation via the portal vein. 2000 Transplant. Proc. pmid:10995965
Soltero L et al. Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects. 2003 Transplant. Proc. pmid:12826147
Levy GA Neoral is superior to FK 506 in liver transplantation. 1998 Transplant. Proc. pmid:9723293
Glanemann M et al. Higher immunosuppressive efficacy of mycophenolate mofetil in combination with FK 506 than in combination with cyclosporine A. 2000 Transplant. Proc. pmid:10812095
Tahir W et al. Diffuse Alveolar haemorrhage: a fatal complication after alemtuzumab induction therapy in renal transplantation. Transplant. Proc. pmid:25645795
Moura Neto A et al. Clinical Profile of Patients With Diabetes Mellitus and Liver Transplantation: Results After a Multidisciplinary Team Intervention. 2018 Transplant. Proc. pmid:29661438
Mühlbacher F Tacrolimus versus cyclosporin microemulsion in liver transplantation: results of a 3-month study. 2001 Feb-Mar Transplant. Proc. pmid:11267317
Duzova A et al. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. 2003 Transplant. Proc. pmid:14697926
Lin CY et al. Effects of FK 506 on the biochemical markers in canine lung allograft rejection. 1991 Transplant. Proc. pmid:1721445
Morales E et al. Conversion from cyclosporine to FK 506 as rescue therapy in renal transplantation with poorly steroid-responsive acute rejection. 1999 Transplant. Proc. pmid:10500562
Jost U et al. FK 506 treatment of intractable rejection after liver transplantation. 1993 Transplant. Proc. pmid:7689276
Nardo B et al. Evidence of microchimerism after pretransplant blood transfusion and FK 506 in liver xenograft. 2000 Transplant. Proc. pmid:11134771
Miyata Y et al. Development of xenogeneic microchimerism correlated with graft outcome in hamster-to-rat heart xenotransplantation. 1998 Transplant. Proc. pmid:9723548
Chamienia A et al. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results. 2014 Transplant. Proc. pmid:25380901
Kocak H et al. Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: better 2-year graft and patient survival than with a higher mycophenolate mofetil dose. 2005 Transplant. Proc. pmid:16213288
Abe T et al. Risk factors for development of new-onset diabetes mellitus and progressive impairment of glucose metabolism after living-donor liver transplantation. 2014 Transplant. Proc. pmid:24767367
Bresci S et al. Case report: cystic fibrosis, lung transplantation, and the novel H1N1 flu. 2010 Jul-Aug Transplant. Proc. pmid:20692461